Geniebiome
Founded 2020 · 25 employees on LinkedIn · 1 known investors
GenieBiome (G-NiiB) develops microbiome-modifying technology and therapeutic candidates supported by clinical trials, using next-generation sequencing. The company focuses on treating human diseases through microbiome-based solutions.
Also known as G-NiiB · G-NiiB GenieBiome · GenieBiome
Investors · 1
Company profile
researched Aug 2026G-NiiB GenieBiome is a microbiome science company that translates gut microbiome research into therapeutic and diagnostic products for human diseases. It operates two stated platforms: a Discovery Platform built around a databank of over 8,000 consistently analysed stool samples with more than 1,000 longitudinal metadata points per sample across health and disease states, and a Therapeutic Platform that moves lead microbial candidates from discovery through characterisation, manufacturability assessment and human testing.
The discovery work combines deep metagenomic analysis with machine-learning models to identify species, strains, genes and functional pathways across eight common diseases, and integrates extensive metadata (medical history, drugs, diet, lifestyle) to distinguish health- from disease-associated species. The company states it applies these platform technologies to early disease detection as well as to food and drug development. On the therapeutics side, it uses whole-genome-sequencing-directed isolation techniques to target uncultured and anaerobic portions of the gut microbiome, maintains a biobank of novel human-derived isolates from healthy donor stool, characterises candidates in in vitro, ex vivo, in vivo and animal models, and develops microbial consortia intended to address multiple indications.
Business model
The company develops microbiome-derived products spanning food and drug development, positions itself for investment and partnership arrangements, and conducts pilot and clinical studies with local and international institutions.
Traction
Stated assets include a databank of over 8,000 analysed stool samples with over 1,000 longitudinal metadata points each, a biobank of novel human-derived microbial isolates, and global publications and awards.
Latest developments
Recent company news items cover an expansion into microbiome-led hair wellness and a national honour received by Prof. Siew Ng.
▸Full profile — market position, technology, go-to-market, geography
Market position
The company describes its approach as one of the first and largest Asian human microbial data-driven approaches to therapeutics development.
Technology
Next-generation and whole-genome sequencing, deep metagenomic analysis and AI/machine-learning models are used to identify microbial signatures and foundation species; a proprietary WGS-directed isolation approach targets uncultured and anaerobic gut organisms, feeding a biobank of human-derived isolates that are developed into single or combined microbial candidates.
Go-to-market
The company works through strategic partners and research collaborations, including partnership with the Microbiota-I Center (MaGIC) to expand its discovery databank, and partners with local and international institutions for clinical testing.
Human disease areas addressed span eight common diseases, with products aimed at early disease detection and therapeutic use; the company also targets investors and R&D partners.
Geography
Operations are presented as having a global presence with a dedicated China chapter, and the underlying data emphasis is on Asian human microbiome cohorts.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsCompany news item announcing a move into microbiome-led hair wellness.
Company news item honouring Prof. Siew Ng on receiving a national honour.
GenieBiome Diagnostics Discovery Platform maintains a partnership with the Microbiota-I Center (MaGIC) to expand its microbiome databank for data-driven product discovery.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- Geniebiomegeniebiome.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Geniebiome do?
- G-NiiB GenieBiome develops microbiome-based therapeutics and diagnostics from a large Asian human gut microbiome databank.
- Who are Geniebiome's investors?
- Geniebiome's investors include Beyond Ventures.